Clinical Trials Directory

Trials / Terminated

TerminatedNCT00673439

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
3 (actual)
Sponsor
University of Louisville · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).

Detailed description

Currently, standard treatment of HIT involves the transition from a direct thrombin inhibitor (a type of anticoagulant or "blood thinner") to warfarin, a different type of anticoagulant. Direct thrombin inhibitors (DTIs) require IV administration and frequent blood draws for dose adjustments, which can lead to prolonged hospitalization. DTIs also affect blood test measurements, making it difficult to determine proper dosages of warfarin. Fondaparinux is a drug that is approved by the FDA for the treatment of blood clots in deep veins and in the lungs. Fondaparinux is not FDA approved for the treatment of HIT. However, an increasing number of doctors are using fondaparinux instead of DTIs to treat HIT. Although fondaparinux appears to be more convenient and predictable than DTI medications, more research is needed to support its use as a treatment for HIT.

Conditions

Interventions

TypeNameDescription
DRUGfondaparinuxDosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
DRUGwarfarinDosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks

Timeline

Start date
2007-11-01
Primary completion
2011-09-01
Completion
2011-09-01
First posted
2008-05-07
Last updated
2019-11-08
Results posted
2013-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00673439. Inclusion in this directory is not an endorsement.